Viking Therapeutics Stock (ISIN: US92686J1060) Surges on Obesity Drug Momentum and Insider Buying

Viking Therapeutics advances its obesity drug VK2735 to Phase 3 trials, with recent insider purchases and valuation models suggesting significant upside, drawing attention from European investors eyeing US biotech opportunities.

Viking Therapeutics stock (ISIN: US92686J1060), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, has gained traction amid progress in its lead obesity candidate VK2735. The company recently completed enrollment in key Phase 3 trials for both subcutaneous and oral formulations, positioning it as a contender in the booming GLP-1/GIP agonist market dominated by larger players. This development, coupled with fresh insider buying, underscores growing confidence in the pipeline's potential to deliver blockbuster revenues.

As of: 15.03.2026

By Dr. Elena Hartmann, Senior Biotech Analyst for US Life Sciences with a European Investor Focus. Tracking obesity drug pipelines and their implications for DACH portfolios.

Current Market Snapshot: Momentum Builds Post-Phase 3 Advancement

Viking Therapeutics shares have shown resilience, posting a 22.86% return over the past 30 days and a 15.34% one-year total shareholder return as of recent data. The three-year performance stands at approximately 3x, reflecting renewed momentum despite a minor 1.44% dip in the last 90 days. This uptick aligns with the company's announcement of substantial progress in VK2735's Phase 3 program, including near-completion of enrollment in subcutaneous and oral studies.

Insider activity further bolsters the bullish case: On March 9, 2026, insider Neil William Aubuchon purchased 4,475 shares valued at approximately $149.91K, signaling strong internal belief in upcoming catalysts. Meanwhile, institutional moves are mixed, with Baker Bros. Advisors LP acquiring new shares and Braidwell LP trimming its stake by 47.2% in the prior quarter. For European investors, particularly in Germany, Austria, and Switzerland, this NASDAQ-listed name offers exposure to high-growth biotech without direct Xetra listing, accessible via international brokers.

Pipeline Spotlight: VK2735's Dual Formulation Edge

At the core of Viking's value proposition is VK2735, a dual GLP-1/GIP agonist targeting obesity with both injectable and oral versions in parallel development. The Phase 3 subcutaneous trial enrollment is largely complete, while oral studies are advancing toward initiation, including a potential maintenance strategy. This flexibility addresses patient preferences for non-injectable options, potentially expanding market penetration beyond Eli Lilly's Mounjaro or Novo Nordisk's Wegovy.

Obesity treatments represent a trillion-dollar addressable market, with GLP-1 drugs driving explosive demand. Viking's progress de-risks the asset, moving it closer to pivotal data readouts expected in the coming years. For DACH investors, accustomed to rigorous EMA standards, Viking's US FDA pathway offers a complementary bet, especially as European regulators scrutinize similar assets for approval.

Valuation Analysis: 61.6% Undervalued Per Leading Models

Valuation narratives peg Viking Therapeutics' fair value at $92.72, implying 61.6% upside from the recent close around $35.63. This assessment hinges on VK2735's revenue ramp-up and margin expansion, projecting a sharp earnings swing via high-margin drug sales post-approval. The model emphasizes parallel development of subcutaneous and oral forms, enhancing market reach and supporting sustained growth.

However, risks temper enthusiasm: a $359.6 million net loss highlights cash burn in clinical stages, with success hinging on Phase 3 outcomes. Biotech peers trade at premiums for approved assets, but Viking's pre-revenue status demands patience. European investors, facing lower yields in traditional sectors, may find this risk-reward profile appealing for portfolio diversification into innovative therapies.

Business Model: Clinical-Stage Biotech with Focused Pipeline

Viking Therapeutics operates as a pure-play clinical-stage biotech, concentrating on metabolic diseases without commercial products yet. Key metrics include pipeline progression, cash runway, and partnership potential rather than revenues or EBITDA. The company's strategy leverages VK2735 as a cornerstone, with additional assets in earlier stages providing optionality.

Cash position supports ongoing trials, but dilution risk looms without milestones or deals. In the biotech framework, success metrics are trial readouts, regulatory filings, and buyouts by big pharma. For Swiss and German funds emphasizing longevity, Viking's targeted approach contrasts with diversified pharma giants, offering higher beta exposure to obesity trends.

European and DACH Investor Perspective

While not listed on Xetra or Deutsche Boerse, Viking Therapeutics stock (ISIN: US92686J1060) is readily accessible to European retail and institutional investors via platforms like Trade Republic or Swissquote. The obesity epidemic resonates in Europe, with rising demand for weight-loss therapies amid healthcare cost pressures. DACH portfolios, heavy in defensive names, increasingly allocate to US biotech for growth, viewing Viking as a proxy for the GLP-1 wave.

Currency dynamics add nuance: a weakening euro against the USD amplifies returns for continental investors. Regulatory alignment between FDA and EMA could facilitate eventual European launches, enhancing appeal. Recent insider buys align with broader sentiment, potentially catalyzing fund inflows from Zurich and Frankfurt.

Operating Environment: GLP-1 Market Dynamics

The obesity drug sector is white-hot, with GLP-1 agonists reshaping healthcare economics. Viking enters a field led by Novo Nordisk and Eli Lilly, but differentiates via oral formulation convenience. Demand drivers include comorbidities like diabetes and cardiovascular disease, with global prevalence fueling adoption.

Supply constraints and pricing power sustain margins, but competition intensifies. Viking's Phase 3 progress positions it for 2027-2028 data, potentially ahead of some rivals. European markets, with public healthcare systems, prioritize cost-effective oral options, aligning with Viking's strategy.

Risks and Catalysts: Balancing the Biotech Gamble

Primary risks include clinical failures, where Phase 3 misses could erase gains, given Viking's single-asset reliance. Cash burn of hundreds of millions necessitates funding, risking dilution. Regulatory hurdles and manufacturing scale-up add uncertainty.

Catalysts abound: positive topline data, partnerships, or acquisition rumors could drive multiples expansion. Analyst upgrades, like recent UBS and JPM hikes on peers, suggest similar potential. For risk-tolerant DACH investors, upcoming milestones offer defined entry points.

Competition and Sector Context

Viking competes with behemoths but carves a niche with dual agonists and orals. Lilly's orforglipron and Novo's oral semaglutide set benchmarks, yet Viking's GIP component may yield superior efficacy. Smaller biotechs face takeover risks, a positive for shareholders.

Sector tailwinds include AI-driven discovery and expanding indications. Viking's valuation discount reflects execution risk but embeds upside if successful.

Capital Allocation and Balance Sheet Health

As a pre-commercial entity, Viking prioritizes R&D spend, with no dividends or buybacks. Net losses reflect investment phase, but sufficient runway supports Phase 3. Future milestones could enable non-dilutive financing.

Insider alignment via purchases mitigates agency risks. European investors value prudent cash management, a watchpoint here.

Outlook: High-Conviction Bet on Obesity Revolution

Viking Therapeutics embodies biotech's high-stakes allure, with VK2735 poised to disrupt. Undervaluation signals opportunity, tempered by risks. For English-speaking investors in Europe, it diversifies into megatrends.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.